Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
Haematologica
; 92(5): 686-9, 2007 May.
Article
en En
| MEDLINE
| ID: mdl-17488695
ABSTRACT
Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Polietilenglicoles
/
Doxorrubicina
/
Linfoma Cutáneo de Células T
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Haematologica
Año:
2007
Tipo del documento:
Article
País de afiliación:
Italia